<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00810264</url>
  </required_header>
  <id_info>
    <org_study_id>CELESTIAL</org_study_id>
    <nct_id>NCT00810264</nct_id>
  </id_info>
  <brief_title>Post Approval Registry of Corox OTW, Endocardial, Left Ventricular Steroid Lead, Bipolar</brief_title>
  <acronym>CELESTIAL</acronym>
  <official_title>CELESTIAL Post Approval Registry: Corox OTW, Endocardial, Left Ventricular Steroid Lead, Bipolar Post Approval Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to confirm the long-term safety and reliability of the Corox
      OTW BP left ventricular (LV) pacing lead. As a condition of approval, the FDA required that a
      registry documenting the post approval clinical experience of these leads be designed and
      implemented.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an FDA-required, multi-center, prospective, non-randomized, data collection
      registry. Eligible patients must have been successfully implanted with a Corox OTW BP, Corox
      OTW-S BP, or Corox OTW-L BP LV lead with a BIOTRONIK CRT device and consented and enrolled
      between 7-180 days following implant. At least 2500 patients will be enrolled in this
      post-approval registry, and each patient will be followed for five years post-implant.

      Safety will be evaluated based on the analysis of the overall incidence of lead-related
      adverse events that require additional invasive intervention. In addition, each individual
      adverse event will be separately investigated. Lead parameters for sensing, pacing
      thresholds, and impedance will also be evaluated. Reporting of all adverse events will be
      performed twice a year in order to identify and characterize any trends in adverse events,
      failure modes, or failure rates.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">November 2, 2018</completion_date>
  <primary_completion_date type="Actual">November 2, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Who Are Free of Complications Related to the Corox LV Lead</measure>
    <time_frame>5 years</time_frame>
    <description>The overall incidence of serious adverse events that require additional invasive intervention to resolve, related to the Corox BP LV leads implanted with either BIOTRONIK CRT-P or CRT-D devices.This was evaluated as a serious adverse event free-rate (SAEFR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Experiencing Individual Complications</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluation of the individual types of serious adverse events contributing to primary outcome 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Successful Biventricular Pacing in Subjects at the 5 Year In-office Visit.</measure>
    <time_frame>5 years</time_frame>
    <description>Successful biventricular pacing in a BIOTRONIK CRT device at scheduled CELESTIAL registry follow-up visits through 5 years post-implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Experiencing Serious Adverse Event Excluded From Primary Safety Endpoint</measure>
    <time_frame>5 years</time_frame>
    <description>Serious adverse event rates for SAEs excluded from primary safety endpoint through 5 years post-implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corox BP LV Lead Pacing Threshold Measurements</measure>
    <time_frame>5 years</time_frame>
    <description>Pacing threshold measurements for the all Corox BP LV lead models at scheduled CELESTIAL registry through 5 years post-implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corox BP LV Lead Sensing Measurements</measure>
    <time_frame>5 years</time_frame>
    <description>Sensing measurements for the all Corox BP LV lead models at scheduled CELESTIAL registry through 5 years post-implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corox BP LV Lead Impedance Measurements</measure>
    <time_frame>5 years</time_frame>
    <description>Impedance measurements for the all Corox BP LV lead models at scheduled CELESTIAL registry through 5 years post-implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pacing Threshold Measurements Per Corox BP LV Lead Model</measure>
    <time_frame>5 years</time_frame>
    <description>Pacing threshold measurements for the Corox OTW BP LV lead, the Corox OTW-S BP LV lead, and the Corox OTW-L BP LV lead.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensing Measurements Per Corox BP LV Lead Model</measure>
    <time_frame>5 years</time_frame>
    <description>Sensing measurements for the Corox OTW BP LV lead, the Corox OTW-S BP LV lead, and the Corox OTW-L BP LV lead.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impedance Measurements Per Corox BP LV Lead Model</measure>
    <time_frame>5 years</time_frame>
    <description>Impedance measurements for the Corox OTW BP LV lead, the Corox OTW-S BP LV lead, and the Corox OTW-L BP LV lead.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Incidence of Primary Endpoint 1 Serious Adverse Events for Each Corox BP Lead Model</measure>
    <time_frame>5 years</time_frame>
    <description>Overall incidence of serious adverse events that meet the primary endpoint 1 criteria will be evaluated separately for each Corox BP lead model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Individual Types of Primary Endpoint 2 Adverse Events Will be Evaluated Separately for Each Corox BP Lead Model</measure>
    <time_frame>5 years</time_frame>
    <description>Incidence of individual types of serious adverse events contributing to primary endpoint 2 will be evaluated separately for each Corox BP lead model.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2499</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Data Collection Group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CRT Therapy - LV Lead Registry</intervention_name>
    <description>Collecting long-term safety and efficacy data on a market-released left ventricular lead.</description>
    <arm_group_label>Data Collection Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be obtained from the investigators' general patient population according to
        the inclusion and exclusion criteria described below.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Successfully implanted BIOTRONIK CRT system, including a Corox BP LV lead, from 7-180
             days prior to enrollment

          -  Able to understand the nature of the registry and give informed consent

          -  Available for follow-up visits on a regular basis at the investigational site

          -  Age greater than or equal to 18 years

        Exclusion Criteria:

          -  Enrolled in any IDE clinical study

          -  Planned cardiac surgical procedures or interventional measures within the next 6
             months

          -  Expected to receive a heart transplant within 1 year

          -  Life expectancy less than 1 year

          -  Presence of another life-threatening, underlying illness separate from their cardiac
             disorder

          -  Pregnancy

          -  Inability to provide date of implant, devices implanted, age, gender, and whether the
             patient experienced any protocol-defined adverse events since implant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfield</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hawthorne</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>National City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Watsonville</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Davenport</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Smyrna Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valparaiso</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hammond</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lanham</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lapeer</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Crystal City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glen Ridge</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Middletown</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Steubenville</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salem</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chinchilla</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pottstown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yardley</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brownsville</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingwood</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nacogdoches</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fredericksburg</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>December 17, 2008</study_first_submitted>
  <study_first_submitted_qc>December 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2008</study_first_posted>
  <results_first_submitted>October 8, 2019</results_first_submitted>
  <results_first_submitted_qc>November 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 29, 2019</results_first_posted>
  <last_update_submitted>November 11, 2019</last_update_submitted>
  <last_update_submitted_qc>November 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Long-term safety and reliability of a bipolar left ventricular lead on congestive heart failure patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 16, 2010</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT00810264/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT00810264/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BIOTRONIK Corox BP LV Lead</title>
          <description>Subjects consented and implanted with a BIOTRONIK Corox BP LV lead.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2499"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="946"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1553"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="191"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by subject or physician</title>
              <participants_list>
                <participants group_id="P1" count="721"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="641"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics are provided when available, subjects without available baseline characteristics are not included in the number of participants analyzed in this section.</population>
      <group_list>
        <group group_id="B1">
          <title>BIOTRONIK Corox BP LV Lead</title>
          <description>Subjects consented and implanted with a BIOTRONIK Corox BP LV lead.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2498"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.4" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="724"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1774"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1805"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="244"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="220"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>inches</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.7" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="194.4" spread="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Who Are Free of Complications Related to the Corox LV Lead</title>
        <description>The overall incidence of serious adverse events that require additional invasive intervention to resolve, related to the Corox BP LV leads implanted with either BIOTRONIK CRT-P or CRT-D devices.This was evaluated as a serious adverse event free-rate (SAEFR).</description>
        <time_frame>5 years</time_frame>
        <population>The evaluable subject population is the sum of the total unique subjects who completed the 5-year follow-up and/or who experienced a primary endpoint adverse event.</population>
        <group_list>
          <group group_id="O1">
            <title>BIOTRONIK Corox BP LV Lead</title>
            <description>Subjects consented and implanted with a BIOTRONIK Corox BP LV lead.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Are Free of Complications Related to the Corox LV Lead</title>
          <description>The overall incidence of serious adverse events that require additional invasive intervention to resolve, related to the Corox BP LV leads implanted with either BIOTRONIK CRT-P or CRT-D devices.This was evaluated as a serious adverse event free-rate (SAEFR).</description>
          <population>The evaluable subject population is the sum of the total unique subjects who completed the 5-year follow-up and/or who experienced a primary endpoint adverse event.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="946"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.19" lower_limit="92.50" upper_limit="95.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The primary safety endpoint 1 hypothesis was evaluated by performing an exact, non-inferiority test comparing a binomial proportion (overall SAEFR at 5 years) to 92.5%, with a non-inferiority delta of 5%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Binomial Proportion</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Experiencing Individual Complications</title>
        <description>Evaluation of the individual types of serious adverse events contributing to primary outcome 1.</description>
        <time_frame>5 years</time_frame>
        <population>The evaluable subject population is the sum of the total unique subjects who completed the 5-year follow-up and/or who experienced a primary endpoint adverse event.</population>
        <group_list>
          <group group_id="O1">
            <title>BIOTRONIK Corox BP LV Lead</title>
            <description>Subjects consented and implanted with a BIOTRONIK Corox BP LV lead.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Experiencing Individual Complications</title>
          <description>Evaluation of the individual types of serious adverse events contributing to primary outcome 1.</description>
          <population>The evaluable subject population is the sum of the total unique subjects who completed the 5-year follow-up and/or who experienced a primary endpoint adverse event.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="946"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lead dislodgement (&gt;180 days post-implant)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.28" lower_limit="2.24" upper_limit="4.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal pacing impedance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" lower_limit="1.13" upper_limit="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conductor fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" lower_limit="0.17" upper_limit="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malposition, excess slack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" lower_limit="0.00" upper_limit="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Successful Biventricular Pacing in Subjects at the 5 Year In-office Visit.</title>
        <description>Successful biventricular pacing in a BIOTRONIK CRT device at scheduled CELESTIAL registry follow-up visits through 5 years post-implant.</description>
        <time_frame>5 years</time_frame>
        <population>The subjects analyzed in this outcome must have been consented, implanted with a BIOTRONIK Corox BP LV lead, and completed an in-office 5 year visit. Subjects who did not complete an in-office 5 year visit are excluded from this analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>BIOTRONIK Corox BP LV Lead</title>
            <description>Subjects consented and implanted with a BIOTRONIK Corox BP LV lead completing an in-office 5 year visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Successful Biventricular Pacing in Subjects at the 5 Year In-office Visit.</title>
          <description>Successful biventricular pacing in a BIOTRONIK CRT device at scheduled CELESTIAL registry follow-up visits through 5 years post-implant.</description>
          <population>The subjects analyzed in this outcome must have been consented, implanted with a BIOTRONIK Corox BP LV lead, and completed an in-office 5 year visit. Subjects who did not complete an in-office 5 year visit are excluded from this analysis population.</population>
          <units>percentage of CRT pacing</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="611"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Experiencing Serious Adverse Event Excluded From Primary Safety Endpoint</title>
        <description>Serious adverse event rates for SAEs excluded from primary safety endpoint through 5 years post-implant.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIOTRONIK Corox BP LV Lead</title>
            <description>Subjects consented and implanted with a BIOTRONIK Corox BP LV lead.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Experiencing Serious Adverse Event Excluded From Primary Safety Endpoint</title>
          <description>Serious adverse event rates for SAEs excluded from primary safety endpoint through 5 years post-implant.</description>
          <units>Percent of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LV lead cardiac perforation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LV lead high pacing threshold, no lead capture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LV lead diaphragmatic / pectoral stimulation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LV lead dislodgement (&lt;180 days post-implant)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RV pacing lead related adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Device related adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA lead related adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Implant procedure related adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICD lead related adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other high pacing threshold</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corox BP LV Lead Pacing Threshold Measurements</title>
        <description>Pacing threshold measurements for the all Corox BP LV lead models at scheduled CELESTIAL registry through 5 years post-implant.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIOTRONIK Corox BP LV Lead</title>
            <description>Subjects consented and implanted with a BIOTRONIK Corox BP LV lead.</description>
          </group>
        </group_list>
        <measure>
          <title>Corox BP LV Lead Pacing Threshold Measurements</title>
          <description>Pacing threshold measurements for the all Corox BP LV lead models at scheduled CELESTIAL registry through 5 years post-implant.</description>
          <units>V</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corox BP LV Lead Sensing Measurements</title>
        <description>Sensing measurements for the all Corox BP LV lead models at scheduled CELESTIAL registry through 5 years post-implant.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIOTRONIK Corox BP LV Lead</title>
            <description>Subjects consented and implanted with a BIOTRONIK Corox BP LV lead.</description>
          </group>
        </group_list>
        <measure>
          <title>Corox BP LV Lead Sensing Measurements</title>
          <description>Sensing measurements for the all Corox BP LV lead models at scheduled CELESTIAL registry through 5 years post-implant.</description>
          <units>mV</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.94" spread="7.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corox BP LV Lead Impedance Measurements</title>
        <description>Impedance measurements for the all Corox BP LV lead models at scheduled CELESTIAL registry through 5 years post-implant.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIOTRONIK Corox BP LV Lead</title>
            <description>Subjects consented and implanted with a BIOTRONIK Corox BP LV lead.</description>
          </group>
        </group_list>
        <measure>
          <title>Corox BP LV Lead Impedance Measurements</title>
          <description>Impedance measurements for the all Corox BP LV lead models at scheduled CELESTIAL registry through 5 years post-implant.</description>
          <units>ohms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="726.5" spread="250.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pacing Threshold Measurements Per Corox BP LV Lead Model</title>
        <description>Pacing threshold measurements for the Corox OTW BP LV lead, the Corox OTW-S BP LV lead, and the Corox OTW-L BP LV lead.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Corox OTW BP</title>
            <description>Subjects consented and originally implanted with a Corox OTW BP lead.</description>
          </group>
          <group group_id="O2">
            <title>Corox OTW-S BP</title>
            <description>Subjects consented and originally implanted with a Corox OTW-S BP lead.</description>
          </group>
          <group group_id="O3">
            <title>Corox OTW-L BP</title>
            <description>Subjects consented and originally implanted with a Corox OTW-L BP lead.</description>
          </group>
        </group_list>
        <measure>
          <title>Pacing Threshold Measurements Per Corox BP LV Lead Model</title>
          <description>Pacing threshold measurements for the Corox OTW BP LV lead, the Corox OTW-S BP LV lead, and the Corox OTW-L BP LV lead.</description>
          <units>V</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="686"/>
                <count group_id="O2" value="1129"/>
                <count group_id="O3" value="684"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="1.01"/>
                    <measurement group_id="O2" value="1.40" spread="1.09"/>
                    <measurement group_id="O3" value="1.53" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensing Measurements Per Corox BP LV Lead Model</title>
        <description>Sensing measurements for the Corox OTW BP LV lead, the Corox OTW-S BP LV lead, and the Corox OTW-L BP LV lead.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Corox OTW BP</title>
            <description>Subjects consented and originally implanted with a Corox OTW BP lead.</description>
          </group>
          <group group_id="O2">
            <title>Corox OTW-S BP</title>
            <description>Subjects consented and originally implanted with a Corox OTW-S BP lead.</description>
          </group>
          <group group_id="O3">
            <title>Corox OTW-L BP</title>
            <description>Subjects consented and originally implanted with a Corox OTW-L BP lead.</description>
          </group>
        </group_list>
        <measure>
          <title>Sensing Measurements Per Corox BP LV Lead Model</title>
          <description>Sensing measurements for the Corox OTW BP LV lead, the Corox OTW-S BP LV lead, and the Corox OTW-L BP LV lead.</description>
          <units>mV</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="686"/>
                <count group_id="O2" value="1129"/>
                <count group_id="O3" value="684"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.82" spread="7.74"/>
                    <measurement group_id="O2" value="13.94" spread="7.59"/>
                    <measurement group_id="O3" value="13.04" spread="7.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impedance Measurements Per Corox BP LV Lead Model</title>
        <description>Impedance measurements for the Corox OTW BP LV lead, the Corox OTW-S BP LV lead, and the Corox OTW-L BP LV lead.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Corox OTW BP</title>
            <description>Subjects consented and originally implanted with a Corox OTW BP lead.</description>
          </group>
          <group group_id="O2">
            <title>Corox OTW-S BP</title>
            <description>Subjects consented and originally implanted with a Corox OTW-S BP lead.</description>
          </group>
          <group group_id="O3">
            <title>Corox OTW-L BP</title>
            <description>Subjects consented and originally implanted with a Corox OTW-L BP lead.</description>
          </group>
        </group_list>
        <measure>
          <title>Impedance Measurements Per Corox BP LV Lead Model</title>
          <description>Impedance measurements for the Corox OTW BP LV lead, the Corox OTW-S BP LV lead, and the Corox OTW-L BP LV lead.</description>
          <units>ohms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="686"/>
                <count group_id="O2" value="1129"/>
                <count group_id="O3" value="684"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="730.3" spread="264.9"/>
                    <measurement group_id="O2" value="734.4" spread="251.7"/>
                    <measurement group_id="O3" value="709.2" spread="233.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Incidence of Primary Endpoint 1 Serious Adverse Events for Each Corox BP Lead Model</title>
        <description>Overall incidence of serious adverse events that meet the primary endpoint 1 criteria will be evaluated separately for each Corox BP lead model.</description>
        <time_frame>5 years</time_frame>
        <population>The evaluable subject population for each group is the sum of the total unique subjects who completed the 5-year follow-up and/or who experienced a primary endpoint adverse event in the group.</population>
        <group_list>
          <group group_id="O1">
            <title>Corox OTW BP</title>
            <description>Subjects consented and originally implanted with a Corox OTW BP lead.</description>
          </group>
          <group group_id="O2">
            <title>Corox OTW-S BP</title>
            <description>Subjects consented and originally implanted with a Corox OTW-S BP lead.</description>
          </group>
          <group group_id="O3">
            <title>Corox OTW-L BP</title>
            <description>Subjects consented and originally implanted with a Corox OTW-L BP lead.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Incidence of Primary Endpoint 1 Serious Adverse Events for Each Corox BP Lead Model</title>
          <description>Overall incidence of serious adverse events that meet the primary endpoint 1 criteria will be evaluated separately for each Corox BP lead model.</description>
          <population>The evaluable subject population for each group is the sum of the total unique subjects who completed the 5-year follow-up and/or who experienced a primary endpoint adverse event in the group.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="401"/>
                <count group_id="O3" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.17" lower_limit="4.43" upper_limit="10.85"/>
                    <measurement group_id="O2" value="6.48" lower_limit="4.28" upper_limit="9.36"/>
                    <measurement group_id="O3" value="3.38" lower_limit="1.56" upper_limit="6.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Individual Types of Primary Endpoint 2 Adverse Events Will be Evaluated Separately for Each Corox BP Lead Model</title>
        <description>Incidence of individual types of serious adverse events contributing to primary endpoint 2 will be evaluated separately for each Corox BP lead model.</description>
        <time_frame>5 years</time_frame>
        <population>The evaluable subject population for each group is the sum of the total unique subjects who completed the 5-year follow-up and/or who experienced a primary endpoint adverse event in the group.</population>
        <group_list>
          <group group_id="O1">
            <title>Corox OTW BP</title>
            <description>Subjects consented and originally implanted with a Corox OTW BP lead.</description>
          </group>
          <group group_id="O2">
            <title>Corox OTW-S BP</title>
            <description>Subjects consented and originally implanted with a Corox OTW-S BP lead.</description>
          </group>
          <group group_id="O3">
            <title>Corox OTW-L BP</title>
            <description>Subjects consented and originally implanted with a Corox OTW-L BP lead.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Individual Types of Primary Endpoint 2 Adverse Events Will be Evaluated Separately for Each Corox BP Lead Model</title>
          <description>Incidence of individual types of serious adverse events contributing to primary endpoint 2 will be evaluated separately for each Corox BP lead model.</description>
          <population>The evaluable subject population for each group is the sum of the total unique subjects who completed the 5-year follow-up and/or who experienced a primary endpoint adverse event in the group.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="401"/>
                <count group_id="O3" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lead dislodgement (&gt;180 days post-implant)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" lower_limit="1.73" upper_limit="6.49"/>
                    <measurement group_id="O2" value="3.49" lower_limit="1.92" upper_limit="5.79"/>
                    <measurement group_id="O3" value="2.63" lower_limit="1.06" upper_limit="5.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal pacing impedance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" lower_limit="0.58" upper_limit="4.13"/>
                    <measurement group_id="O2" value="2.99" lower_limit="1.56" upper_limit="5.17"/>
                    <measurement group_id="O3" value="0.38" lower_limit="0.01" upper_limit="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conductor fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" lower_limit="0.58" upper_limit="4.13"/>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="NA">Unable to obtain confidence interval for 0 subjects</measurement>
                    <measurement group_id="O3" value="0" lower_limit="NA" upper_limit="NA">Unable to obtain confidence interval for 0 subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malposition, excess slack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="NA">Unable to obtain confidence interval for 0 subjects</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="NA">Unable to obtain confidence interval for 0 subjects</measurement>
                    <measurement group_id="O3" value="0.38" lower_limit="0.01" upper_limit="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Implant to study exit (up to 5 years post-implant)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BIOTRONIK Corox BP LV Lead</title>
          <description>Subjects consented and implanted with a BIOTRONIK Corox BP LV lead.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="641" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="281" subjects_at_risk="2499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CHF</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>Device migration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>Hypotensive arrest / hemodynamic collapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>ICD lead T-wave oversensing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>ICD lead cardiac perforation with or without tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>ICD lead dislodgement</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>ICD lead high pacing threshold, intermittent capture, no lead capture</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>ICD lead impedance out of range, high impedance, potential conductor fracture</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>ICD lead impedance out of range, low Impedance, potential insulation break</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>ICD lead inability to defibrillate or pace</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>ICD lead oversensing or lead noise</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>ICD lead undersensing or loss of sensing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>ICD lead, Riata lead externalized</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>ICD lead, unknown, inadequate source documentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>Inappropriate shocks</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>LV lead abnormal pacing impedance, high impedance</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>LV lead cardiac perforation with or without tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>LV lead conductor fracture</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>LV lead dislodgement</sub_title>
                <counts group_id="E1" events="65" subjects_affected="61" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>LV lead excess slack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>LV lead high pacing threshold, intermittent capture, no lead capture</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>LV lead related diaphgramatic / pectoral stimulation</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>Non-functioning RA lead</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>Pocket pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>RA lead dislodgement</sub_title>
                <counts group_id="E1" events="30" subjects_affected="29" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>RA lead high pacing threshold, intermittent capture, no lead capture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>RA lead impedance out of range, high impedance, potential conductor fracture</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>RA lead impedance out of range, low impedance, potential insulation break</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>RA lead oversensing or lead noise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>RA lead undersensing or loss of sensing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>RV pacing lead dislodgement</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>RV pacing lead impedance out of range, high impedance, potential conductor fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>RV pacing lead noise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>Suspected generator failure requiring opening of pulse generator pocket</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Twiddler's syndrome</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="2499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Implant procedure related infection</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>Pocket infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>Secondary infection</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="2499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin erosion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>Trauma related dehiscence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac perforation with or without tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>High defibrillation thresholds due to inappropriate lead placement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>Implant procedure related damage to the lead</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>LV lead dislodgement during RV lead extraction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>Loose set screw</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>Non-healing pocket dehiscence requiring intervention</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>Open heart surgery causing LV lead dislodgement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>Persistent arm of unknown cause</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>Pocket pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>RA lead dislodgement during LV lead placement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>SVC perforation during laser lead extraction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>Subclavian vein occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="2499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ICD lead high pacing threshold, intermittent capture, no lead capture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>ICD lead oversensing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>ICD lead oversensing or lead noise</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>LV lead abnormal pacing impedance, high impedance</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>LV lead dislodgement</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>High pacing threshold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>LV lead high pacing threshold, intermittent capture, no lead capture</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>LV lead related diaphgramatic / pectoral stimulation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>RA lead dislodgement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>RA lead high pacing threshold, intermittent capture, no lead capture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>RA lead impedance out of range, high impedance, potential conductor fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>RA lead impedance out of range, low impedance, potential insulation break</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>RA lead noise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>RA lead oversensing or lead noise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>Twiddler's syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Arrhythmias</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>Coronary sinus dissection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>Diaphragmatic stimulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>Incompletely healed incision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>Left subclavian vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
              <event>
                <sub_title>Non-healing pocket dehiscence requiring intervention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2499"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Studies Engineer Group Manager</name_or_title>
      <organization>BIOTRONIK</organization>
      <phone>800-547-0394</phone>
      <email>celestial@biotronik.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

